论文部分内容阅读
本文比较苯酯丙脯酸和巯甲丙脯酸联用氢氯噻嗪(DHCT)以及甲基多巴治疗中至重度原发性高血压的疗效、安全性和耐受情况。 20名中至重度原发性高血压病人,参加为期22周的双盲平行试验。开头4周基础治疗期,受试者每人每天服用DHCT50mg,如果基础期末卧位舒张压≥100mmHg,该病人将继续进入随机试验期,每人每天服用巯甲丙脯酸25mg(一日3次)加苯酯丙脯酸安慰剂(一日2次),或者苯酯丙脯酸5mg(一日2次)加巯甲丙脯酸安慰剂(一日3次)。对受试者每二周测量一次卧位及立位动脉压和心率,在第2、4、10、16和22周时作全血计
This article compares the efficacy, safety and tolerability of phenylpropionic acid and captopril in combination with hydrochlorothiazide (DHCT) and methyldopa for the treatment of moderate to severe essential hypertension. Twenty patients with moderate to severe essential hypertension were enrolled in a 22-week, double-blind, parallel trial. The first 4 weeks of the initial treatment period, the subjects taking DHCT 50mg daily, if the end of the basal period diastolic blood pressure ≥ 100mmHg, the patient will continue to enter the randomized trial period, captopril 25mg per person per day (three times a day ) Plus phentermine placebo (2 times a day), or 5 mg of phenylpropanoid (2 times a day) plus captopril placebo (3 times a day). Subjects were measured once every two weeks in the supine and standing arterial pressure and heart rate, at the 2nd, 4th, 10th, 16th and 22nd weeks for the whole blood count